Tag: PROACT Xa

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ — Artivion, Inc. ( NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if […]